Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY

v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
Total
Common Stock Warrants
Prefunded Warrants
Common Stock
Common Stock
Common Stock Warrants
Common Stock
Prefunded Warrants
Additional Paid-In Capital
Additional Paid-In Capital
Common Stock Warrants
Additional Paid-In Capital
Prefunded Warrants
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020       288,074,415            
Beginning balance at Dec. 31, 2020 $ 450,786     $ 288,074     $ 38,896,693     $ (38,733,981)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense (in shares)       600,000            
Stock-based compensation expense 146,580     $ 600     145,980      
Exercise warrant (in shares)         67,166,667 11,800,000        
Exercise warrant   $ 4,030,000 $ 11,800   $ 67,167 $ 11,800   $ 3,962,833    
Net loss (2,160,517)                 (2,160,517)
Ending balance (in shares) at Mar. 31, 2021       367,641,082            
Ending balance at Mar. 31, 2021 2,478,649     $ 367,641     43,005,506     (40,894,498)
Beginning balance (in shares) at Dec. 31, 2021       476,108,445            
Beginning balance at Dec. 31, 2021 5,864,166     $ 476,108     52,644,221     (47,256,163)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Stock-based compensation expense (in shares)       150,000            
Stock-based compensation expense 150,358     $ 150     150,208      
Exercise warrant (in shares)     19,666,667     19,666,667        
Exercise warrant     $ 1,967     $ 19,667     $ (17,700)  
Net loss (3,043,399)                 (3,043,399)
Ending balance (in shares) at Mar. 31, 2022       495,925,112            
Ending balance at Mar. 31, 2022 $ 2,973,092     $ 495,925     $ 52,776,729     $ (50,299,562)